Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (840)	12/17/2001 2:19:18 PM
From: jt101	Read Replies (2) \| Respond to of 2557

Remedy for common cold could arrive next fall By Anita Manning, USA TODAY CHICAGO — Scientists say they may be closing in on a long-sought improvement on Mom's chicken soup — an anti-viral treatment for the common cold. An experimental drug, pleconaril, targets a group of cold germs called picornaviruses, easing symptoms and shortening the cold's duration. If approved, it would be the first anti-viral cold medication and could be on the market by next fall. Picornaviruses are responsible for about two-thirds of all common colds, says Harley Rotbart, a professor of pediatrics and microbiology at the University of Colorado School of Medicine in Denver. There are 160 to 170 different picornaviruses, he says, "and each of them can cause the cold. But that group has enough internal similarities that a single approach to treatment is potentially doable." Rotbart, who is a consultant to drug developer ViroPharma, says the medication starts making patients feel better within 24 hours and makes the cold disappear a day sooner. "If you've got a miserable cold, you're missing work and the kids are missing school, and you've got a medication that is non-sedating and attacks the root of the infection, that is significant," he says. Final clinical data will be presented today at the Interscience Conference on Antimicrobial Agents and Chemotherapy by Frederick Hayden of the University of Virginia in Charlottesville. Preliminary results in the study, which involved 2,096 patients, found that those whose colds were caused by picornaviruses recovered in 6.3 days if they took pleconaril three times a day for five days. The cold dragged on for 7.3 days for those who got a placebo. Rotbart says 65% of those in the study had colds caused by picornaviruses, but the drug, now under review by the Food and Drug Administration, won't help the remaining 35% infected with other cold viruses. There is a need for an alternative to over-the-counter cold remedies, which can affect the ability to think and perform daily activities more than people realize, says neuropsychologist Gary Kay of Georgetown University School of Medicine in Washington, D.C. Kay says the average adult endures two to four colds a year, and, in a survey of 1,000 people, 30% report having missed a day of school or work because of a cold. Three-fourths report treating colds with non-prescription antihistamines or decongestants, and most say they feel no side effects, he says. "But if we measure their ability to perform, we find impaired performance in absence of feeling drowsy or sleepy," Kay says. "That's the danger. If you don't feel drowsy, you are not going to take precautions." How welcome a new anti-viral cold medication will be to the average cold sufferer remains to be seen, says family physician Daniel Van Durme of Tampa. "The symptoms of cold are caused by the body's immune response to the virus," he says. An anti-viral medication "will slow it a little, but this is not the elusive cure for the common cold." What will be more important, he says, is if it reduces the spread of colds, which can cause serious illness in nursing homes and other vulnerable populations. usatoday.com

To: scaram(o)uche who wrote (840)	12/17/2001 6:23:19 PM
From: Cacaito	Respond to of 2557

That is the CHEAP way Aventis figure out how not to pay for Picovir, is an Aventis insurance, the $50 millions are going to pay for the sales force (Aventis itself has a freeze on new Reps positions), of course Vphm is building one for them. Aventis goes risk free with picovir at the FDA, if failed they end up with a sales force.

To: scaram(o)uche who wrote (840)	12/17/2001 7:01:41 PM
From: RCMac	Read Replies (2) \| Respond to of 2557

Pleconaril featured in a 2+ minute story on NBC news a few minutes ago, giving Viropharma's name (but not Picovir), stressing that it attacks the virus not just the symptoms, "actually helps people with colds rather than just waiting for them to get better", expected to be a lifesaver for some, and to sell big when approved next year (with 62 million annual colds in US), etc. Very favorable story. Most such stories on NBC are repeated in the news hours across the evening on CNBC and MSNBC, I believe at 10:00 PM and 1:00 AM (ET) on CNBC and at 9 and midnight on MSNBC. --RCM